Penn Researchers Identify a New Marker That Predicts Progressive Kidney Failure and Death

A high level of a hormone that regulates phosphate is associated with an increased risk of kidney failure and death among chronic kidney disease (CKD) patients, according to a recent study led by researchers at the University of Miami and the Perelman School of Medicine at the University of Pennsylvania and funded by the National Institute of Diabetes and Digestive Diseases and Kidney Diseases (NIDDK). Results were published in the June 15 issue of the Journal of the American Medical Association.

CKD affects over 20 million Americans and costs the nation nearly $58 billion per year. The findings come from the Chronic Renal Insufficiency Cohort (CRIC) Study, led by principal investigator Harold I. Feldman, MD, MSCE, professor of Medicine, Renal Electrolyte and Hypertension Division, and professor of Epidemiology, and co-principal investigator J. Richard Landis, PhD, professor of Biostatistics.

The CRIC Study follows nearly 4,000 individuals with CKD for the purpose of identifying risk factors for the progression of kidney disease and the development of cardiovascular disease. The current investigation was led by Myles Wolf, MD, MMSc at the University of Miami and was based on a median follow-up period of 3.5 years, during which 266 study participants died and 410 developed kidney failure requiring renal replacement therapy. The study's Scientific and Data Coordinating Center is located at the Perelman School of Medicine.

Click here to view the full release.